Ortho evra, Evra(norelgestromin)
Evra (norelgestromin) is a small molecule pharmaceutical. Norelgestromin was first approved as Ortho evra on 2001-11-20. It is used to treat amenorrhea and uterine hemorrhage in the USA. It has been approved in Europe to treat contraception.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
| therapeutics | D013812 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethinyl estradiol
+
Norelgestromin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ORTHO EVRA | Johnson & Johnson | N-021180 DISCN | 2001-11-20 | 1 products, RLD |
Hide discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | 3 | 1 | 4 | 3 | 2 | 13 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | — | — | — | 1 |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | 1 | 1 | ||
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | — | — | 1 | 1 |
| Menstruation disturbances | D008599 | HP_0400007 | N91.5 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NORELGESTROMIN |
| INN | norelgestromin |
| Description | Norelgestromin, or norelgestromine, sold under the brand names Evra and Ortho Evra among others, is a progestin medication which is used as a method of birth control for women. The medication is available in combination with an estrogen and is not available alone. It is used as a patch that is applied to the skin.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC |
Identifiers
| PDB | — |
| CAS-ID | 53016-31-2 |
| RxCUI | 326374 |
| ChEMBL ID | CHEMBL1200807 |
| ChEBI ID | — |
| PubChem CID | 62930 |
| DrugBank | DB06713 |
| UNII ID | R0TAY3X631 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 423 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xulane, Zafemy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
239 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more